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Methods: Blood, plasma and serum samples were spiked with known 
quantities of human DNA. To optimize the yield of DNA, we inves-
tigated the effects of changes in the blood collection and process-
ing, storage and DNA extraction protocols. We compared two DNA 
puriﬁcation methods, the QIAamp blood DNA kit (QIAGEN) (with 
and without proteinase K pre-digestion) and phenol/chloroform DNA 
extraction after heat denaturation (5 minutes at 95˚C). Extracted DNA 
was quantiﬁed using the PicoGreen assay and its quality was checked 
by conventional PCR analysis for the p53 gene. 
Results: Using the standard QIAamp protocol, the efﬁciency of DNA 
extraction from serum was 13.8 ± 5.9% (Mean ± SD). Pre-incubation 
with proteinase K (0.4 mg/ml, QIAGEN) at 37˚C for 2 hours signiﬁcant-
ly increased the DNA recovery (p<0.0001, unpaired t-test), but longer 
incubation time and incubation at 50˚C did not improve the DNA yield 
further. Further improvements in the efﬁciency of the QIAamp protocol 
were obtained by increasing the volume of elution buffer, but reloading 
the columns and using different buffers did not improve the yield. Using 
the phenol/chloroform extraction method after heat denaturation, the ef-
ﬁciency of DNA extraction was 52.7 ± 4.6% (Mean ± SD), which is sig-
niﬁcantly better than the QIAamp protocol (p<0.0001, unpaired t-test). 
Delays in processing blood samples reduced the DNA yield. Importantly, 
all the recovered DNA was of quality suitable for PCR analysis.
Conclusions: We recommend that blood samples are held on ice for 
no more than 1 hour before plasma/serum separation by double spin. 
Because of its higher efﬁciency, low-cost and good quality products for 
PCR analysis, we prefer the phenol/chloroform circulating DNA isola-
tion method with heat denaturation. 
BSTB: Prognostic Factors
P2-063 BSTB: Prognostic Factors Posters, Tue, Sept 4 
Clinical and prognostic significance of serum carcinoembryonic 
antigen level in patients with IIIB and IV stage non-small cell lung 
cancer: A prospective study
Arrieta, Oscar1 Martínez-Velasco, Abril2 Silva-Godinez, Juan C.3 Flores 
Estrada, Diana4 Falcon, Javier5 Guzman, Enrique5 Martinez, Luis5 de la 
Garza, Jaime4 
1 Instituto Nacional de Cancerologia, Mexico, México 2 Universidad 
Nacional Autónoma de México, México, México 3 Universidad Nacio-
nal Autonoma de Mexico / Instituto Nacional de Cancerologia, Mexico, 
Mexico 4 Instituto Nacional de Cancerologia, Mexico, Mexico 5 Instituto 
Nacional de Enfermedades Respiratorias, Mexico, Mexico 
Background: Previous studies have shown pre and post-operative 
serum carcinoembryonic antigen (CEA) levels are a prognostic factor 
in patients with non-small cell lung cancer (NSCLC). We prospectively 
investigated the clinical and prognostic signiﬁcance of serum CEA 
elevation as well as the clinical and pathological characteristics in 
patients with stage IIIB and IV NSCLC. 
Methods: From March 2005 to January 2007, 308 patients with IIIB 
and IV stage NSCLC were included. Several chemotherapy proto-
cols including gemcitabine, vinorelbine or paclitaxel combined with 
cisplatin, carboplatin, or erlotinib were used. Serum CEA levels were 
obtained before and after 2 cycles of treatment. Stage was determined 
by CT and bone scans. 
Results: One hundred twenty patients had brain CT scan at diagnosis 
due to neurological symptoms. Twenty eight per cent had stage IIIB, 
and 61.4% stage IV disease. Eighteen per cent had CNS metastases at 
the time of diagnosis. Histological type was adenocarcinoma in 69.1% 
and squamous in 30.9%. Mean serum CEA concentration was 11.3 ng/
ml ± 24.5 with a median of 6.7 (range 0.2 to 4578). Patients with CEA 
levels > 10, 20, 50 and 100 were 43.6, 32.5, 24 and 17.9%; respec-
tively. Associated factors with CEA >20 were age >62 (p=0.02), stage 
IV (p=0.05), CNS metastases (p=0.0001) and histologic type (p=0.01). 
However, logistic regression analysis showed the only associated fac-
tors were histologic type (p=0.0001) and CNS metastases (p=0.0001). 
Patients with CEA elevation >20 had a hazard ratio of 26.3 (CI 11.2 to 
61.6) for the development of brain metastases. Overall survival associ-
ated factors included poor status performance (p=0.006), tobacco use 
(p=0.05), CEA elevation (p=0.0022), CNS metastases (p=0.0157), and 
male gender (p=0.08). There were no differences between stages (IIIB 
vs. IV) and hepatic metastases. The associated factors with survival by 
Cox proportional hazards regression multivariate analysis were poor 
performance status (p=0.05) and CEA elevation (p=0.008). The inde-
pendent factors associated with CEA elevation were adenocarcinoma 
histologic type and brain metastases. 
Conclusions: Patients with stage IIIB and IV NSCLC and with serum 
CEA >20 without neurological symptoms could beneﬁt from early CT 
brain scan. In this group of patients, the most important independent 
factors for survival were poor performance status and CEA elevation.
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The aim of this study was to assess the prognostic impact on survival of 
Cyfra 21-1, CEA and NSE in NSCLC pts receiving complete resec-
tion. Eight-hundred and twenty nine pts with histologically proven 
NSCLC stage I-IIIA receiving complete resection were included (stage 
I- 381; stage II- 212; stage IIIA - 227). The serum levels of all mark-
ers were measured using commercially available immunoassays and 
were obtained immediately before surgery. With a medium follow-up 
of 88 months, patients with initial Cyfra 21-1 higher than 3.3 ng/ml 
had a very signiﬁcant worse prognosis (p<.00001). Higher than 9.8 
ng/ml baseline CEA showed also a bad prognostic impact, but only for 
adenocarcinoma (p=0.0023). NSE showed no prognostic importance. 
In a Cox regression model, Cyfra 21-1 proved to be, among 25 other 
usual independent factors, the strongest independent prognostic factor 
for both overall survival and disease-free interval. In fact, the overall 
5-years survival-rate for all pts in stage I was 54.3%, but increase to 
75.7% in the 268 pts (70.3%) with normal baseline Cyfra 21-1 and 
strongly decrease to less than 15% for the 113 pts (29.7%) with higher 
than 3.3 ng/ml baseline Cyfra 21-1 levels. Very similar results were ob-
tained with stage II and IIIA pts and were presented in our communica-
tion. For those pts with higher Cyfra 21-1 values adjuvant (used in 248 
pts) and particularly neo-adjuvant chemotherapy (used in 88 pts) seems 
to reduce clearly these critical survival results. Survival comparisons 
will be presented in detail. 
